Robbie Kattappuram
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robbie Kattappuram has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Ajit Kumar Sharma
National Cancer Institute 1 Developmental Therapeutics Branch, Center for Cancer Research National Institutes of Health, Bethesda, Maryland
37 shared publications - Anish Thomas
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
37 shared publications - Baktiar O. Karim
Frederick National Laboratory for Cancer Research
37 shared publications - Brett Schroeder
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
37 shared publications - Chante Graham
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
37 shared publications - Christophe E. Redon
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
37 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Trial protocol dose limiting toxicity criteria
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Trial protocol dose limiting toxicity criteria
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Whole exome sequencing results
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Whole exome sequencing results
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Berzosertib pharmacodynamic assessment
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Berzosertib pharmacodynamic assessment
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Comparison of treatment-related adverse events with the combination of berzosertib and topotecan
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Comparison of treatment-related adverse events with the combination of berzosertib and topotecan
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Whole exome sequencing results
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Whole exome sequencing results